Concert Pharmaceuticals - CNCE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $19.67
  • Forecasted Upside: 134.69%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.38
▲ +0.01 (0.12%)

This chart shows the closing price for CNCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Concert Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNCE

Analyst Price Target is $19.67
▲ +134.69% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Concert Pharmaceuticals in the last 3 months. The average price target is $19.67, with a high forecast of $25.00 and a low forecast of $17.00. The average price target represents a 134.69% upside from the last price of $8.38.

This chart shows the closing price for CNCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Concert Pharmaceuticals. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2023JonestradingReiterated RatingBuy ➝ HoldLow
1/19/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
1/19/2023JMP SecuritiesDowngradeMarket PerformLow
1/19/2023Truist FinancialDowngradeBuy ➝ HoldLow
9/13/2022Truist FinancialBoost TargetBuy$22.00 ➝ $25.00Low
8/24/2022JonestradingInitiated CoverageBuy$17.00Low
3/4/2022HC WainwrightReiterated RatingBuy$17.00High
11/12/2021JMP SecuritiesLower TargetOutperform$17.00 ➝ $10.00Low
10/5/2021MizuhoReiterated RatingBuy$13.00 ➝ $9.00High
7/2/2021HC WainwrightReiterated RatingBuy$17.00Low
5/4/2021MizuhoReiterated RatingBuy$13.00Medium
2/2/2021Truist FinancialLower Target$30.00 ➝ $22.00Low
2/2/2021HC WainwrightReiterated RatingBuy$25.00 ➝ $17.00Low
12/16/2020Berenberg BankInitiated CoverageBuy$25.00Low
11/4/2020JMP SecuritiesInitiated CoverageOutperformHigh
10/2/2020MizuhoReiterated RatingBuy$18.00High
9/14/2020MizuhoReiterated RatingBuy$18.00High
6/1/2020MizuhoReiterated RatingBuy$18.00High
3/30/2020Jefferies Financial GroupInitiated CoverageBuy$23.00High
2/27/2020Stifel NicolausDowngradeHold$8.00 ➝ $11.00High
1/29/2020MizuhoReiterated RatingBuy$18.00Low
1/24/2020HC WainwrightReiterated RatingBuy$25.00High
1/22/2020SunTrust BanksReiterated RatingBuy$25.00 ➝ $30.00Low
1/22/2020JMP SecuritiesReiterated RatingOutperformLow
12/3/2019SunTrust BanksBoost TargetBuy$25.00Medium
11/8/2019MizuhoReiterated RatingBuy$18.00High
10/3/2019HC WainwrightLower TargetBuy$29.00 ➝ $25.00Low
9/30/2019SunTrust BanksLower TargetBuy$30.00 ➝ $20.00Medium
9/30/2019Janney Montgomery ScottReiterated RatingFair Value ➝ Buy$13.00 ➝ $10.00Medium
9/30/2019MizuhoReiterated RatingBuy$29.00 ➝ $18.00High
9/27/2019Stifel NicolausDowngradeBuy ➝ Hold$18.00 ➝ $8.00Low
9/4/2019Janney Montgomery ScottSet TargetBuy$16.00Low
9/4/2019MizuhoBoost TargetBuy$23.00 ➝ $29.00High
8/2/2019MizuhoSet TargetBuy$23.00Low
8/2/2019HC WainwrightReiterated RatingBuy$29.00Low
6/24/2019SunTrust BanksInitiated CoverageBuy$30.00 ➝ $30.00Medium
6/13/2019HC WainwrightReiterated RatingBuy ➝ Buy$26.00 ➝ $29.00High
6/13/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$14.00 ➝ $16.00High
5/17/2019MizuhoReiterated RatingBuy$23.00Low
5/3/2019HC WainwrightReiterated RatingBuy$26.00High
5/3/2019MizuhoReiterated RatingBuyHigh
4/10/2019UBS GroupSet TargetBuy$19.00 ➝ $13.00Medium
4/9/2019JMP SecuritiesLower TargetOutperform$26.00 ➝ $20.00Low
4/9/2019MizuhoLower TargetBuy ➝ Buy$26.00 ➝ $23.00Low
4/9/2019Stifel NicolausLower TargetBuy ➝ Buy$27.00 ➝ $18.00High
3/1/2019HC WainwrightReiterated RatingBuyMedium
11/13/2018UBS GroupSet TargetBuy$19.00Medium
9/13/2018Janney Montgomery ScottInitiated CoverageNeutral ➝ NeutralHigh
8/3/2018HC WainwrightReiterated RatingBuyLow
8/2/2018MizuhoReiterated RatingBuy$27.00High
5/4/2018HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $26.00Low
4/10/2018MizuhoReiterated RatingBuy$27.00Medium
3/9/2018MizuhoUpgradeNeutral ➝ Buy$23.00 ➝ $27.00High
3/2/2018HC WainwrightReiterated RatingBuy ➝ Buy$21.00 ➝ $25.00High
3/1/2018MizuhoReiterated RatingHold$23.00High
2/13/2018MizuhoReiterated RatingHold$23.00Low
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/11/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/10/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/9/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 6 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 6 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Concert Pharmaceuticals logo
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $8.38
Low: $8.36
High: $8.41

50 Day Range

MA: $6.23
Low: $4.34
High: $8.40

52 Week Range

Now: $8.38
Low: $2.57
High: $8.44

Volume

1,049,673 shs

Average Volume

3,656,447 shs

Market Capitalization

$401.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Concert Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Concert Pharmaceuticals in the last year: HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Jonestrading, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for CNCE.

What is the current price target for Concert Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Concert Pharmaceuticals in the last year. Their average twelve-month price target is $19.67, suggesting a possible upside of 134.7%. Truist Financial Co. has the highest price target set, predicting CNCE will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Concert Pharmaceuticals in the next year.
View the latest price targets for CNCE.

What is the current consensus analyst rating for Concert Pharmaceuticals?

Concert Pharmaceuticals currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CNCE, but not buy more shares or sell existing shares.
View the latest ratings for CNCE.

What other companies compete with Concert Pharmaceuticals?

How do I contact Concert Pharmaceuticals' investor relations team?

Concert Pharmaceuticals' physical mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 860-0045 and its investor relations email address is [email protected] The official website for Concert Pharmaceuticals is www.concertpharma.com. Learn More about contacing Concert Pharmaceuticals investor relations.